Search hospitals > New York > New York
NYU Langone Health
Claim this profileNew York, New York 10016
Global Leader in Skin Cancer
Global Leader in Uterine Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Breast Cancer
658 reported clinical trials
260 medical researchers
Summary
NYU Langone Health is a medical facility located in New York, New York. This center is recognized for care of Skin Cancer, Uterine Tumors, Non-Small Cell Lung Cancer, Lung Cancer, Breast Cancer and other specialties. NYU Langone Health is involved with conducting 658 clinical trials across 1,679 conditions. There are 260 research doctors associated with this hospital, such as Sharon L. Gardner, Bhavana Pothuri, Paul Oberstein, MD, and Vamsidhar Velcheti, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Uterine Tumors
Global LeaderStage IV
Stage III
FGFR3 positive
Top PIs
Sharon L. GardnerLaura and Isaac Perlmutter Cancer Center at NYU Langone7 years of reported clinical research
Expert in Cerebral Gliomas
Expert in Brain Tumor
33 reported clinical trials
83 drugs studied
Bhavana PothuriLaura and Isaac Perlmutter Cancer Center at NYU Langone2 years of reported clinical research
Expert in Ovarian Cancer
Studies Endometrial Cancer
21 reported clinical trials
33 drugs studied
Paul Oberstein, MDNYU Langone Health3 years of reported clinical research
Expert in Pancreatic Cancer
Studies Stomach Cancer
21 reported clinical trials
49 drugs studied
Vamsidhar Velcheti, MDLaura and Isaac Perlmutter Cancer Center at NYU Langone2 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
32 drugs studied
Clinical Trials running at NYU Langone Health
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Cancer
Lazy Eye
Colorectal Cancer
Deep Vein Thrombosis
Breast Cancer
Lymphoma
Post-Traumatic Stress Disorder
Melanoma
FF-10832 + Pembrolizumab
for Cancer
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Recruiting3 awards Phase 2
Surgery vs Stereotactic Ablative Radiotherapy
for Lung Cancer
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Recruiting2 awards Phase 312 criteria
MYTX-011
for Lung Cancer
This trial is testing MYTX-011, a new medication that targets advanced lung cancer cells with specific genetic markers. It uses an antibody to guide a powerful drug directly to the cancer cells to kill them.
Recruiting1 award Phase 19 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at NYU Langone Health?
Where is NYU Langone Health located?
Who should I call to ask about financial aid or insurance network?
What insurance does NYU Langone Health accept?
What awards or recognition has NYU Langone Health received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.